A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis
Principal Investigator
Robert CarruthersOverview
Body Locations and Systems
Multiple SclerosisClinicalTrials.gov#
NCT02792218Status
Closed for RecruitmentStudy Start/End
Mar 22, 2017 to Feb 1, 2020Locations
UBC Hospital, Vancouver General Hospital
Name/Title
Karina Grigore, Research CoordinatorPhone
604-827-1892Email Address
karina.grigore@ubc.caPurpose of Study
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.